DOJ Investigates Group Linked to Reid Hoffman Over E. Jean Carroll Lawsuit Funding 
Salesforce Q1 FY2027 Earnings Beat Expectations Despite Soft Q2 Revenue Outlook 
MongoDB Q1 FY2027 Earnings Beat Expectations, Raises Full-Year Outlook 
Autodesk Beats Q1 Estimates, Acquires MaintainX for $3.6 Billion 
SpaceX IPO Could Become Largest in History with $1.8 Trillion Valuation Target 
HP Q2 2026 Earnings Beat Expectations Despite Memory Chip Pressure 
European EV Sales Surge in April 2026 as Tesla and Chinese Automakers Gain Ground 
Elon Musk Explores Possible Tesla-SpaceX Merger Amid Growing AI Investments 
Australia Sues 3M for Over A$2 Billion Over PFAS Firefighting Foam Contamination 
Rising Airfares May Challenge Cruise Industry Growth Ahead of 2027 Booking Season 
Mega IPOs Like SpaceX and OpenAI Could Reshape S&P 500 and Nasdaq 100 Portfolios in 2026 
Snowflake Stock Soars 30% After Q1 Earnings Beat and Major AWS AI Partnership 
Sable Offshore Wins Key Court Battle Over California Oil Pipeline 
US Quantum Stocks Surge After $2 Billion Government Investment 
Xiaomi Shares Drop After Weak Q1 Earnings Amid Rising Smartphone Costs 
Dell Raises 2027 Revenue Forecast as AI Server Demand Drives Record Quarterly Results 
Synopsys Q2 FY2026 Earnings Beat Driven by AI and Semiconductor Demand 
Samsung Bioepis Co. Ltd.'s commercial partner Organon will supply its Hadlima autoimmune disease treatment to the United States after winning an order from the U.S. Department of Veterans Affairs. It was agreed that U.S.-based Organon would deliver the biosimilar Hadlima drugs for five years.
Organon will now deliver Hadlima biosimilar treatment to the Department of Veterans Affairs (V.A.). This well-known drug is mainly used for medicating rheumatoid arthritis, spondyloarthritis, and psoriasis. According to The Korea Economic Daily, AbbVie Inc., a pharmaceutical company headquartered in North Chicago, Illinois, developed the original drug.
Orders from the U.S.
The latest order was revealed by Organon, the partner company of Samsung Bioepis based in the U.S. On Wednesday, Feb. 21, the firm said that Organon won a bidding contract to supply Hadlima to the American government agency. Consequently, Organon will supply Hadlima to hospitals under the Ministry of Veterans Affairs for the next five years.
The Veterans Affairs
The VA is a government agency for veterans in the United States. It provides benefits in various fields, such as medical care and finance, and is building a general hospital-level hospital network and medical infrastructure throughout the United States.
"America's veterans deserve access to quality medicines at a lower cost. We are proud to support the more than nine million people enrolled in the VA healthcare system through this collaboration, which is a great example of industry and public sector working together," Kevin Ali, Organon CEO, said in a press release. "We applaud the VA for its leadership in championing biosimilars and including all three of Organon's biosimilars available in the US on its formulary."
Photo by: Organon Media
